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A b s t r A c t
During the early phase of an acute myocardial infarction (MI), current consensus is 
that reperfusion of the infarct-related artery (IRA) should be implemented as soon 
as possible, more effectively accomplished via percutaneous coronary intervention 
(PCI). The clinical approach to the occluded IRA late after MI remains controversial, 
but current practice shows a strong trend in favor of PCI, which is based on the late 
open artery hypothesis. However, late PCI on IRAs also has the potential for harm 
from procedure-related complications. An attempt is made herein to critically over-
view the current data on this important topic, mainly based on recent meta-analyses 
with somewhat diverging results, indicating that clinical judgment and an individual-
ized approach still remains a valid guide.
During the early phase of an acute myocardial infarction (MI), current consensus 
is that reperfusion of the infarct-related artery (IRA) should be implemented as soon 
as possible. According to the current ACC/AHA/SCAI and ESC guidelines primary 
percutaneous coronary intervention (PCI) is the treatment of choice when delivered 
rapidly (no longer than 0 minutes from patient’s first medical contact), by experienced 
teams in high-volume centers, specifically when the time from the onset of symptoms 
is shorter than 12 hours.1,2 In this early phase the main goal is myocardial salvage, 
which is critically time-dependent. Prompt restoration of blood flow reduces infarct 
size, preserves global left ventricular function, and thus improves patient survival. 
Unfortunately, the number of patients treated within 12 hours of the onset of 
symptoms is still disappointing, since 8.5% to 40% of patients present beyond 12 
hours.3 The clinical approach to the occluded IRA late after MI remains variable and 
controversial, but current practice shows a strong trend in favor of PCI, which is based 
on the late open artery hypothesis.4,5 According to this theory late patency of an IRA 
is associated with reduction in adverse post-infarction remodeling, increased electri-
cal stability, and provision of collateral vessels to other coronary beds for protection 
against future events.6 It was initially conceived during the fibrinolytic era when several 
studies suggested that the effects of IRA reperfusion on left ventricular function and 
survival might, to some extent, be independent of one another.7,8 Further support was 
provided by nonrandomized, retrospective studies of patients with a first MI, where 
long-term survival was found to be substantially better among those with anterograde 
flow in the infarct-related artery than among those whose infarct-related artery was 
persistently occluded.,10 Other studies showed that patients with a persistently occluded 
IRA after MI were more likely than those with a patent artery to have late potentials on 
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signal-averaged electrocardiography and inducible ventricular 
tachyarrhythmias during invasive programmed electrical 
stimulation.11,12 The late open artery hypothesis thus forms a 
solid theoretical basis in favor of late intervention in order to 
reperfuse occluded IRAs. However, late PCI on IRAs also 
has the potential for harm from procedure-related complica-
tions, distal embolization of atherothrombotic debris resulting 
in myocardial injury, and loss of recruitable collateral flow to 
other coronary territories.13-15 
r A N D O m I z E D  t r I A L s  t E s t I N G  
t H E  L A t E  O P E N  A r t E r Y  H Y P O t H E s I s
Several randomized trials of small or modest sample sizes 
compared PCI versus medical therapy for total IRA occlusion 
late after MI. Although their results were not definitive, po-
tential improvements in left ventricular function and probably 
even clinical events suggested that late opening of occluded 
arteries after MI should be seriously considered.16-20 These 
studies were followed by the publication of OAT (Occluded 
Artery Trial) in 2006, which was the first large, randomized 
trial to test the late open artery hypothesis.21 This trial tested 
the hypothesis that routine PCI for total occlusion 3 to 28 days 
after MI would reduce the composite endpoint of death, re-
infarction, or class IV heart failure. Stable patients (n =2166) 
with an occluded infarct artery after MI (of whom almost 
20% received fibrinolytic therapy for the index event) were 
randomized to optimal medical therapy and PCI with stenting 
or optimal medical therapy alone. Inclusion criteria included 
total occlusion of the infarct-related artery with TIMI grade 0 
or 1 antegrade flow and left ventricular (LV) ejection fraction 
(LVEF) less than 50% or proximal occlusion of a major epi-
cardial artery with large myocardial region at risk. Exclusion 
criteria included NYHA class III or IV heart failure, serum 
creatinine greater than 2.5 mg/dL, left main or 3-vessel dis-
ease, clinical instability, or severe inducible ischemia on stress 
testing if the infarct zone was not akinetic or dyskinetic. The 
4-year combined end point was 17.2% in the PCI group and 
15.6% in the medical therapy group (HR 1.16, 5% CI 0.2 
to 1.45, p = 0.2). Re-infarction rates tended to be higher in 
the PCI group, which may have attenuated any benefit in LV 
remodeling. There was no interaction between treatment ef-
fect and any subgroup variable. It should be noted that even in 
the absence of significant effects on hard end points, the OAT 
study showed that patients treated with PCI were significantly 
less likely to have angina at 4, 12, and 24 months, while that 
difference disappeared at the third year of follow up.
The Total Occlusion Study of Canada 2 (TOSCA-2) was 
a substudy of OAT which included 332 patients who were 
submitted to repeated coronary and LV angiography one 
year after randomization.22 Patients in the PCI group had the 
IRA patent in 83% of cases while this was true for only 25% 
of the medically treated patients. Despite this difference no 
significant benefit of the PCI strategy was found concerning 
LV function, in concert with the OAT results. 
These results have challenged the late open artery hy-
pothesis and its clinical implications. Because of the findings 
of the OAT trial a new recommendation was included in the 
latest 2007 focused update23 of the ACC/AHA/SCAI 2005 
PCI guidelines: PCI of a totally occluded infarct artery greater 
than 24 hours after STEMI is not recommended (Class III) 
in asymptomatic patients with 1- or 2-vessel disease if they 
are hemodynamically and electrically stable and do not have 
evidence of severe ischemia. (Level of Evidence: B).
t W O  r E c E N t  m E t A - A N A L Y s E s  
t E s t I N G  t H E  s t r A t E G Y  O f  L A t E  
P c I  t O  r E c A N A L I z E  A N  I r A
The first meta-analysis by Ioannidis and Katritsis24 
included data from the small and medium sized studies pub-
lished before OAT (Table 1), as well as data from OAT trial 
and its sub-study TOSCA-2. The 2617 patients included were 
examined for clinical outcomes including death, MI, death 
or MI and congestive heart failure (CHF), while for 653 of 
them a change in LVEF could be determined. There were no 
statistically significant differences for any clinical outcome, 
with trends for an increase in MI (risk ratio 1.26, P = 0.1) and 
decrease in CHF (risk ratio 0.67, P = 0.1) in the PCI arm. 
The PCI arm showed a slight superiority in LVEF. The authors 
concluded that the open artery hypothesis does not seem to 
translate to clinically meaningful advantages and that benefits 
of late reperfusion do not justify the costs and high radiation 
times for both patients and physicians encountered with inter-
ventions for recanalization of totally occluded IRAs.
In the second and most recent meta-analysis by Abbate et 
al25 studies were included if they compared PCI with medical 
management and randomized clinically stable patients >12 h 
and up to 60 days after acute MI. Studies included were finally 
the same as in the meta-analysis of Ioannidis and Katritsis, 
with the inclusion of four additional studies TOPS,26 ALKK,27 
BRAVE-23 and SWISSI II28 (Table 2). The analysis comprised 
3560 patients yielding significantly improved survival in the 
PCI group (OR: 0.4, 5% CI: 0.26 to 0.4, p = 0.030). These 
benefits were associated with similarly favourable effects 
on cardiac remodeling, such as improved LVEF in the PCI 
group. 
The results of these two meta-analyses initially seem 
contradictory, however one can find an explanation when the 
four additional trials included in the second meta-analysis are 
closely examined. Their inclusion criteria were not adapted 
to strictly test the late open artery hypothesis. The BRAVE- 2 
study, which comprised 365 patients, examined whether rou-
tine PCI of MI latecomers, in the time window of 12-48 hrs 
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after symptom onset, could provide benefit over initial medi-
cal therapy.3 It showed that infarct size can be significantly 
reduced with such a strategy, however only 56.6% of patients 
submitted to PCI were found with an occluded IRA (defined 
as having TIMI flow 0 or I) at the time of intervention. A 
trend towards a reduction of the composite of death, MI or 
stroke at 30 days was also found (relative risk reduction: 33%). 
ALKK study included 300 clinically stable patients, 8-42 days 
after MI.27 The IRA was found occluded in less than one third 
of patients randomized to PCI or medical therapy, and PCI 
was related to a significant mortality reduction (4% versus 
11% with medical therapy), during long-term follow up (56 
months). Re-infarction and the need for revascularization were 
also reduced significantly. The SWISSI II study included 201 
patients, who had ST-elevation MI (STEMI) or non-STEMI 
within the last three months, silent ischemia documented by 
stress imaging and 1 or 2 vessel disease suitable for PCI.28 
Stents were not used and patients were followed for 10 years. 
Death, non fatal MI or revascularization were significantly re-
duced with PCI (HR: 0.33), as was exercise induced ischemia. 
TOPS was a smaller study (87 patients) published in the early 
0s.26 Patients were randomized to PCI or medical therapy if 
at 4-14 days after thrombolysis they had a negative stress test 
and an IRA with ≥50% stenosis. Less than 15% of patients 
had an occluded IRA. Infarct free survival was somehow 
worse with PCI at 1 year (88.7% vs 100%), but angina-free 
survival was better. In general, these four studies added to 
the meta-analysis of Abbate et al25 a large number of patients 
(n=53) with clinical scenarios more encouraging towards an 
interventional strategy. Their addition apparently led to an 
analysis with results in favor of PCI, in contrast to the study 
of Ioannidis and Katritsis24 which included only studies closer 
to the late open artery hypothesis paradigm.
H O W  t O  D E A L  W I t H  t H E  I r A  O f  
A  L A t E c O m E r  I N  c L I N I c A L  P r A c t I c E
According to the latest focused update of the ACC/AHA/
SCAI guidelines23 PCI is recommended (Class I) after suc-
cessful fibrinolysis or in patients not undergoing primary 
reperfusion within the first 12 h, when any of the following is 
true: objective evidence of recurrent MI (class I, C), presence 
of moderate or severe spontaneous or induced ischemia after 
MI (class I, B), cardiogenic shock or hemodynamic instability 
(class I, B). Furthermore, it is reasonable to perform routine 
late PCI after an MI (class IIa, C) in patients with LVEF 
<0.40, heart failure, serious ventricular arrhythmias or even 
documented CHF only during the acute episode with subse-
quent EF >0.40. However, PCI of a totally occluded IRA >24 
h after an STEMI is not recommended (Class III, B – OAT 
contribution) in asymptomatic patients with 1- or 2-vessel 
disease if they are hemodynamically and electrically stable 
and do not have evidence of severe ischemia. 
These latest guidelines mix two groups of patients: those 
successfully submitted to fibrinolysis and latecomers who did 
not benefit from either fibrinolysis or primary PCI. In the first 
group there has been myocardial salvage and the latest ESC 
guidelines recommend routine coronary angiography and, if 
applicable, PCI early after effective thrombolysis (Class I, A) 
up to 24 h after thrombolysis independent from angina and/or 
ischemia.2 The second group, latecomers who did not benefit 
from an early reperfusion (either thrombolysis or primary 
PCI), is quite heterogeneous. On the one hand and accord-
ing to the guidelines, those who are clinically unstable should 
undoubtedly be treated with late PCI. On the other hand, those 
who are clinically stable can differ in many aspects: the time 
from symptom onset to presentation, the number of diseased 
coronary vessels, whether the IRA is occluded or spontane-
ously reperfused, the IRA territory, the presence and extent 
of silent or symptomatic ischemia, the presence of previously 
infracted myocardium, the LVEF and of course numerous 
other factors defining their general medical condition and 
their risk profile.
The OAT results,21 further supported by the meta-analy-
sis of Ioannidis and Katritsis,24 are by strict terms the best 
evidence to date testing the late open artery hypothesis. 
However, their discouraging results should not be interpreted 
as an argument against PCI to recanalize IRAs in all MI late-
comers. There is some debate on whether OAT patients are 
representative of real life treatment scenarios. OAT excluded 
those patients with post-infarction angina and/or moderate to 
severe ischemia. However, one-third to two-thirds of patients 
have residual symptomatic or silent ischemia after AMI.2 
Recruitment in the OAT study was indeed difficult and inter-
rupted early; the explanation could be that many cardiologists 
believed PCI was beneficial for this group, leaving potentially 
less ideal candidates available for randomization. In addition, 
length of follow-up was limited, since less than one-half of the 
patients in OAT had a follow-up that reached 3 years. Of note, 
despite the lack of benefit concerning death, MI or NYHA 
class IV heart failure, there was significant relief from angina 
found with PCI during the first two years of follow up. 
The most recent meta-analysis of Abbate et al.25 gave 
results in favor of PCI for a mixed population of latecomers 
after MI, but only after including data from trials not suitable 
to strictly test the late open artery hypothesis. 
The final message is that clinically stable latecomers after 
MI are a diverse group, and decisions about late PCI on their 
IRAs should be individualized. The correct approach should 
not be to routinely recanalize any IRA, but rather to search for 
correct arguments before doing so, after thoroughly but swiftly 
analyzing any given patient’s clinical situation. For the mo-
ment the existing evidence seems still incomplete and current 
guidelines, although helpful, can not replace the physician’s 
judgment in many clinical scenarios of real practice. 
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